Dempze Nancy E Abb Vie Inc. Transaction History

Dempze Nancy E

$162 Million
Q3 2024

A detailed history of Dempze Nancy E transactions in Abb Vie Inc. stock. As of the latest transaction made, Dempze Nancy E holds 6,892 shares of ABBV stock, worth $1.24 Million. This represents 0.84% of its overall portfolio holdings.

Number of Shares

6,892

Previous 1,780 287.19%

Holding current value

$1.24 Million

Previous $305,000 346.23%

% of portfolio

0.84%

Previous 0.23%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$163.84 - $199.33 $837,550 - $1.02 Million	5,112 Added 287.19%	6,892 $1.36 Million
Q2 2024 Aug 12, 2024	BUY	$154.79 - $180.76 $103,244 - $120,566	667 Added 59.93%	1,780 $305,000
Q1 2024 May 13, 2024	BUY	$159.82 - $182.1 $177,879 - $202,677	1,113 New	1,113 $202,000
Q3 2023 Nov 14, 2023	SELL	$133.59 - $154.65 $12,691 - $14,691	-95 Reduced 5.96%	1,498 $223,000
Q2 2023 Aug 14, 2023	SELL	$132.51 - $164.9 $19,876 - $24,735	-150 Reduced 8.61%	1,593 $214,000
Q1 2023 May 10, 2023	SELL	$144.61 - $166.54 $10,556 - $12,157	-73 Reduced 4.02%	1,743 $277,000
Q3 2022 Nov 08, 2022	SELL	$134.21 - $153.93 $7,381 - $8,466	-55 Reduced 2.94%	1,816 $243,000
Q2 2022 Jul 19, 2022	SELL	$137.62 - $174.96 $43,350 - $55,112	-315 Reduced 14.41%	1,871 $286,000
Q1 2022 May 17, 2022	BUY	$131.98 - $163.75 $6,862 - $8,515	52 Added 2.44%	2,186 $355,000
Q4 2021 Feb 08, 2022	SELL	$107.43 - $135.93 $118,710 - $150,202	-1,105 Reduced 34.12%	2,134 $289,000
Q3 2021 Nov 10, 2021	SELL	$106.4 - $120.78 $2,660 - $3,019	-25 Reduced 0.77%	3,239 $349,000
Q2 2021 Aug 09, 2021	SELL	$105.21 - $117.21 $149,503 - $166,555	-1,421 Reduced 30.33%	3,264 $368,000
Q1 2021 May 17, 2021	SELL	$102.3 - $112.62 $2,557 - $2,815	-25 Reduced 0.53%	4,685 $507,000
Q3 2020 Oct 28, 2020	BUY	$85.91 - $100.83 $92,610 - $108,694	1,078 Added 29.68%	4,710 $412,000
Q1 2020 May 07, 2020	SELL	$64.5 - $97.79 $19,350 - $29,337	-300 Reduced 7.63%	3,632 $277,000
Q4 2019 Jan 15, 2020	SELL	$72.13 - $90.25 $2,885 - $3,610	-40 Reduced 1.01%	3,932 $349,000
Q3 2019 Nov 07, 2019	SELL	$62.98 - $75.72 $755 - $908	-12 Reduced 0.3%	3,972 $301,000
Q4 2018 Jan 24, 2019	SELL	$77.85 - $96.01 $31,684 - $39,076	-407 Reduced 9.27%	3,984 $368,000
Q3 2018 Oct 15, 2018	SELL	$88.91 - $98.84 $800 - $889	-9 Reduced 0.2%	4,391 $416,000
Q2 2018 Jul 30, 2018	SELL	$89.78 - $106.23 $23,342 - $27,619	-260 Reduced 5.58%	4,400 $408,000
Q1 2018 Apr 24, 2018	SELL	$92.01 - $123.21 $72,595 - $97,212	-789 Reduced 14.48%	4,660 $441,000
Q4 2017 Feb 02, 2018	BUY	$89.56 - $98.21 $188,076 - $206,241	2,100 Added 62.71%	5,449 $527,000
Q3 2017 Oct 26, 2017	BUY	$69.85 - $89.22 $233,927 - $298,797	3,349	3,349 $297,000

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dempze Nancy E, based on Form 13F filings with the SEC.

News

Stay updated on Dempze Nancy E with notifications on news.

Account